Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic resistant bacteria.

Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

News

Editorial by Henry Chambers, Vance Fowler
Highlights Strategic One Health Approach to Address Antimicrobial Resistance

An editorial titled “Confronting Antimicrobial Resistance Together” by Henry Chambers, MD, and Vance Fowler, MD, was published in the November issue of the American Journal of Physiology – Lung Cellular and Molecular Physiology. The article reinforces the theme of World Antimicrobial Awareness Week 2022, “Preventing Antimicrobial Resistance Together,” and emphasizes the importance of One Health, a unified, transdisciplinary approach that aims to improve health outcomes by recognizing the interconnectedness of humans, animals, and our shared environments.

Drs. Chambers and Fowler use the COVID-19 pandemic as a key example of the need for a One Health approach to antimicrobial resistance (AMR). In 2020, COVID-19 deaths surpassed the number of deaths caused by the “Big Three” infectious diseases: tuberculosis (TB), HIV-AIDS, and malaria. The authors discuss how progress in the prevention and treatment of these illnesses was disrupted by the pandemic, and suggest that COVID-19 likely exacerbated AMR. Prescribing of antibiotics to patients without a bacterial infection, increases in hospitalizations, and overwhelmed diagnostic laboratories, among other factors, potentially could lead to increased rates of AMR.
ARLG Spotlight — Heather King

Heather A. King, Ph.D.
Research Health Scientist, Durham VA Health Care System, Health Services Research and Development, Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT)
Assistant Professor, Department of Population Health Sciences and Division of General Internal Medicine, Duke University School of Medicine

About my role in the ARLG

For more than six years, I have had the opportunity to lead several ARLG patient-reported quality-of-life (QoL) studies on bacterial infections alongside wonderful ARLG collaborators like Drs. Thomas Holland, Sarah Doernberg, and Jessica Howard-Anderson. I also feel privileged to be part of ARLG’s Innovations Working Group under the leadership of Dr. Helen Boucher and to be a member of the Health-Related Quality of Life (HRQoL) Task Force. In addition, I provide expertise on study design and methodology to our U.S. and global colleagues.

About my work on QoL studies

We began our research in bloodstream infection and have expanded our work to address patient-reported HRQoL and its measurement across four major infectious syndromes which include complicated urinary tract infection (cUTI), acute bacterial skin and skin structure infection (ABSSSI), hospital acquired/ventilator associated bacterial pneumonia (HABP/VABP), and complicated intraabdominal infection (cIAI).

Why is this research important?

Engaging patients is crucial to developing treatments for bacterial infections. It is important to capture outcomes that reflect what matters most to patients as they recover.

Our work informs the measurement of patient-reported HRQoL in studies for new antibacterial agents. By incorporating these patient-reported outcome measures into clinical trials, we learn valuable information about the patients’ perspectives on the effects of an intervention including how it influences function across a variety of life domains.
Helen Boucher Cites Progress and Perils Fighting Antimicrobial Resistance

ARLG investigator, Executive Committee Member, and Innovations Working Group Chair, Helen Boucher, MD, FACP, FIDSA, spoke with Contagion about current challenges and progress in combatting antimicrobial resistance (AMR). She sat for the video interview after delivering her Maxwell Finland Lecture, “Running to Stand Still: Progress and Perils with AMR” at IDWeek 2022. The Maxwell Finland Lecture is awarded annually to experts who have contributed to the areas of bacterial pathogenesis, antimicrobial agents, emerging infections, and hospital-acquired infections.

“It [AMR] affects every one of us—you, me, our children—and I think it’s still not really understood and really embraced by many as a problem that affects them today,” says Dr. Boucher. Limited awareness about AMR, lack of antibiotics, and a gap in surveillance data to understand the extent of AMR in the United States are some of her primary concerns.

ARLG Early Faculty Seedling Award Applications Are Open!

As part of our mission to mentor the next generation of researchers, ARLG offers the Early Faculty Seedling Award as a grant opportunity to help early stage investigators develop preliminary data and apply for additional external funding. Applications for this award are now open for submission.

The Early Faculty Seedling Award provides 50% of current salary support per year for protected research for up to two years and up to $25,000 in direct costs for the entire grant period.
research over the next two years.

Who is eligible to apply?

- ID Fellows at the 4th or 5th year of fellowship
- MD or PhD (any discipline) with a faculty appointment of less than five years
- Applicants who work at a US domestic institution for the duration of the award irrespective of citizenship or visa status

The clinical research project may be conducted in the U.S. or internationally.

Learn more

COMBINE Study Summary Now Available!

A lay summary of results has been posted for the Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) and Combination regimen of Ceftazidime-Avibactam with Aztreonam Hollow Fiber Infection Model against NDM-1-producing Enterobacteriaceae (COMBINE HFIM) studies.

Doctors have few options for treating infections caused by antibiotic-resistant Gram-negative bacteria. Like many antibiotics, ceftazidime-avibactam (CZA) and aztreonam (ATM) do not work against some types of bacteria when used alone, but they do work when combined together.

Researchers wondered if combining CZA and ATM could become a new treatment option that is more effective and resilient against the MBLs made by antibiotic-resistant Gram-negative bacteria. CZA and ATM can be prescribed on their own, but doctors do not know when it may be safe to combine the two antibiotics or which doses may work best. To find out, researchers conducted the COMBINE and COMBINE HFIM studies.

Read More

Events

ARLG at IDWeek OnDemand
Many of ARLG’s top leaders were on hand at IDWeek 2022 discussing the latest AMR topics. The event in October featured 140 scientific sessions from ID experts on a variety of interesting subjects.

As a reminder, you can still view any sessions, abstracts, or exhibits you may have missed with OnDemand access. The content is available now through March 2023.

Be sure to see this year’s Maxwell Finland Lecture delivered by ARLG investigator, Executive Committee Member, and Innovations Working Group Chair, Helen Boucher, MD, FACP, FIDSA. Use the ARLG guide to find more exciting sessions and posters you will want to see before time runs out.

---

**Study Milestones**

View recent ARLG study updates.

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHAGE</td>
<td>Study of the Safety and Microbiological Activity of BacterioPHAGEs in Persons with Cystic Fibrosis Colonized with <em>Pseudomonas aeruginosa</em></td>
<td>Enrolling</td>
</tr>
<tr>
<td>REPORT-ABC</td>
<td>Rapid REPORTing of Antimicrobial resistance from Blood Cultures</td>
<td>Published</td>
</tr>
<tr>
<td>SCENE</td>
<td>Screening for Colonization with Resistant Enterobacterales in Neutropenic Patients with Hematologic Malignancies</td>
<td>Closed</td>
</tr>
<tr>
<td>COMBINE</td>
<td>Ceftazidime-Avibactam in Combination with Aztreonam</td>
<td>Published</td>
</tr>
</tbody>
</table>
Recent Publications
View the following recent ARLG publications.


